“Rapamycin slows aging in healthy people.”
Rapamycin has not been shown to slow aging in healthy people, and the one year-long trial in healthy adults missed its main goal.
Taking rapamycin for longevity today means accepting real drug risks for a benefit that has not been shown in people. The safest way to try it is in a registered clinical trial.
If you are interested, search ClinicalTrials.gov for a rapamycin aging trial you could join instead of buying it online.
Safety note: Rapamycin (sirolimus) is a prescription drug used to suppress the immune system after kidney transplants. Its label lists higher risk of infections, mouth sores, higher cholesterol and blood sugar, slow wound healing and drug interactions, and advises avoiding live vaccines; long-term safety of low-dose intermittent use in healthy people is not known.
Talk to a healthcare professional if: you are thinking about taking rapamycin. Use it only through a prescriber who can review interactions, infections, vaccines, planned surgery and lab monitoring, and never from an unverified seller.
The one year-long placebo-controlled trial in healthy adults missed its main outcome and found only a few secondary benefits. It was small, used a compounded drug with low blood levels and was run by a company that sells rapamycin, so it cannot settle the question either way.
Rapamycin has not been shown to slow aging in healthy people, and the one year-long trial in healthy adults missed its main goal. In the PEARL trial, 114 adults who completed 48 weeks of low-dose weekly rapamycin had no change in visceral (belly) fat, the main outcome; women on 10 mg gained some lean mass and reported less pain, and some users reported better well-being. Side effects were similar to placebo, and the trial did not measure aging itself or lifespan.
Rapamycin extends lifespan in mice, and blocking the same pathway extends life in yeast, worms and flies, which makes it a serious research candidate. A 2024 review of 19 human studies found that rapamycin and related drugs improved some immune, heart and skin measures linked to aging, with no clear effect on hormone, muscle or brain measures; in people who already had aging-related diseases, infections and cholesterol went up. Animal longevity and a handful of human healthspan measures are not the same as slower human aging.
- Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, Zalzala S. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. DOI: 10.18632/aging.206235. PMID: 40188830. PMCID: PMC12074816. ClinicalTrials.gov: NCT04488601
- Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longevity. 2024;5(2):e152-e162. DOI: 10.1016/S2666-7568(23)00258-1. PMID: 38310895
- Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. DOI: 10.1038/nature08221. PMID: 19587680. PMCID: PMC2786175
- Northstar Rx LLC. Sirolimus tablets: US prescribing information (DailyMed). Revised May 2026; DailyMed updated May 11, 2026